Nuron Biotech is focused on innovative and improved specialty biologics and vaccines. Nuron’s vision is to bring better biologics to market with enhanced product profiles for better health of patients. Nuron’s Founders and Management team members are veteran biotech executives who have made significant contributions at Pfizer and other biotechnology companies prior to their arrival at Nuron.

Nuron is currently working on products in the three disease areas, Central Nervous Systems (CNS), Wound Healing and Vaccines. Nuron has recently completed acquisition of BaroFeron™. BaroFeron™ is a proprietary recombinant human interferon beta being developed for the treatment of Multiple Sclerosis. Nuron Biotech is currently implementing a clinical and regulatory strategy for taking BaroFeron™ to advanced clinical trials.

Nuron has also acquired rights for a proprietary recombinant human Epidermal Growth Factor (EGF) product. This recombinant human EGF product has been approved and marketed in other countries for Diabetic Foot Ulcers and Burns. Nuron is working with regulatory agencies in US, EU and Japan for initiating advanced clinical studies for approval.

Nuron is currently in discussions with other biotechnology companies to expand the portfolio in the areas of specialty biotech and vaccines.